China Biologic Products
No. 14 East Hushan Road
Taian City
Shandong
China
Tel: 86-538-6203895
Website: http://www.ctbb.com.cn/
Email: ir@ctbb.com.cn
211 articles about China Biologic Products
-
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
3/29/2021
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China , today announced its financial results for the fourth quarter and fiscal year of 2020.
-
China Biologic Reports Financial Results for the Third Quarter of 2020
11/24/2020
China Biologic Products Holdings, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, announced its unaudited financial results for the third quarter of 2020.
-
China Biologic Products to Report Second Quarter 2020 Financial Results
8/10/2020
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China , today announced that the Company plans to release its second quarter 2020 financial results on Monday, August 17, 2020 after the market closes. The Company's management
-
China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction
6/29/2020
China Biologic Products Holdings, Inc. declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic.
-
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction
5/20/2020
China Biologic Products Holdings, Inc. declared that Xinjiang Deyuan Bioengineering Co., Ltd., China Biologic's source plasma supplier and cooperation partner, has materially breached its strategic cooperation with China Biologic by entering into plasma supply arrangements with Southern Shuanglin Bio-Pharmacy Co., Ltd., and that China Biologic will take all necessary measures to protect its rights.
-
China Biologic Products to Report First Quarter 2020 Financial Results
5/12/2020
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China , today announced that the Company plans to release its first quarter 2020 financial results on Wednesday, May 20, 2020 after the market closes. The Company's manage
-
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019
3/12/2020
China Biologic Products Holdings, Inc. announced its financial results for the fourth quarter and fiscal year of 2019.
-
China Biologic Products to Report Fourth Quarter and Fiscal Year 2019 Financial Results
3/3/2020
China Biologic Products Holdings, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, announced that the Company plans to release its fourth quarter and fiscal year 2019 financial results on Thursday, March 12, 2020 after the market closes.
-
China Biologic Reports Financial Results for the Third Quarter of 2019
11/13/2019
China Biologic Products Holdings, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, announced its unaudited financial results for the third quarter of 2019.
-
China Biologic Products to Report Third Quarter 2019 Financial Results
11/4/2019
Company plans to release its third quarter 2019 financial results on Wednesday, November 13, 2019 after the market closes.
-
China Biologic Forms Special Committee to Review "Going Private" Proposal
9/24/2019
China Biologic Products Holdings, Inc. announced that its board of directors has formed a special committee to review and evaluate the previously announced preliminary non-binding "going private" proposal that the Board received on September 18, 2019 from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte.
-
China Biologic Products to Report Second Quarter 2019 Financial Results
7/26/2019
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2019 financial results on Monday, August 5, 2019 after the market closes.
-
China Biologic Reports Financial Results for the First Quarter of 2019
5/10/2019
China Biologic Products Holdings, Inc. announced its unaudited financial results for the first quarter of 2019.
-
China Biologic Products to Report First Quarter 2019 Financial Results
4/30/2019
China Biologic Products Holdings, Inc. announced that the Company plans to release its first quarter 2019 financial results on Friday, May 10, 2019 after the market closes.
-
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018
3/6/2019
China Biologic Products Holdings, Inc. a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2018.
-
China Biologic Reports Financial Results for the Third Quarter of 2018
11/1/2018
3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms
-
China Biologic Responds to Lawsuit Filed in Cayman Islands by Former Chairman
8/28/2018
China Biologic Products Holdings, Inc. today issued the following statement in response to a lawsuit filed against the Company in the Cayman Islands by Mr. David (Xiaoying) Gao, the former Chairman and CEO of the Company who was terminated for cause
-
China Biologic Announces Updates on Unsolicited Acquisition Proposals and Strategic Private Placement
8/24/2018
China Biologic Products Holdings, Inc. today announced that the Company's board of directors (the "Board") has received a letter dated August 23, 2018 from CITIC Capital MB Investment Limited withdrawing its preliminary non-binding proposal dated June 11, 2018, with immediate effect.
-
China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal
8/21/2018
China Biologic Products Holdings, Inc. has received an unsolicited, preliminary non-binding proposal letter from a consortium
-
China Biologic Names Bing Li as New CEO
8/13/2018
Dr. Li has moved from an independent director to an executive director of the Board.